UK

Chronic hepatitis B affects an estimated 3.2 million people in Europe alone and more than 250 million people globally.

The UK Health Security Agency (UKHSA) has launched a targeted vaccination programme, beginning with students residing at the University of Kent.

Sitryx stands to receive development, regulatory, and commercialization milestone payments exceeding USD 500 million, alongside tiered royalties on future sales if any drug from the partnership reaches the market.

Developed jointly by the Drugs for Neglected Diseases initiative and Sanofi, Acoziborole Winthrop represents a substantial improvement over existing therapies, which require either a 10-day oral regimen or combined injections and oral medications for advanced cases.

The expansion also aligns with the government’s National Cancer Plan for England, which focuses on accelerating patient diagnosis and improving access to treatment nationwide.

The company plans to utilize two key facilities for this production: its Oxford, United Kingdom site and its Durham, North Carolina location.

The company will showcase its technology on the ABHI UK Pavilion alongside a robust delegation of UK life sciences and health technology companies.

The deal centers on ozureprubart, an anti-immunoglobulin E (IgE) antibody that could transform how patients manage life-threatening food allergies.

Adults with obesity and a BMI of 30 kg/m² or higher can now use Wegovy at a 7.2mg dose level, which requires three consecutive 2.4mg doses instead of a single injection.

With this latest authorisation, individuals now have access to a long-acting option for prevention rather than daily pill-based regimens.